Xvivo Perfusion AB 

€22.24
6
+€0.28+1.28% Thursday 06:05

Statistics

Day High
20.72
Day Low
20.72
52W High
30.48
52W Low
14.45
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
189.78
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.04
0.06
0.17
0.27
Expected EPS
0.0688008
Actual EPS
N/A

Financials

1.99%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
203.33MRevenue
4.04MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3XV.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap116.33B
Medtronic offers products for cardiac and vascular surgeries, competing in the organ preservation segment.
Boston Scientific
BSX
Mkt Cap149.24B
Boston Scientific competes in the medical devices sector, including technologies for less invasive surgeries.
Stryker
SYK
Mkt Cap136.19B
Stryker provides medical devices for various surgeries, indirectly competing in the organ transplant space.
Intuitive Surgical
ISRG
Mkt Cap189.4B
Intuitive Surgical's robotic-assisted surgical systems can be used in transplant surgeries, offering an alternative to traditional methods.
Edwards Lifesciences
EW
Mkt Cap48.41B
Edwards Lifesciences specializes in heart valves and hemodynamic monitoring, competing in the cardiovascular market.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories offers medical devices, diagnostics, and nutrition products that serve similar patient groups as XVIVO.
Baxter International
BAX
Mkt Cap9.49B
Baxter International provides a range of hospital and renal products, including organ preservation solutions.
Zimmer Biomet
ZBH
Mkt Cap19.92B
Zimmer Biomet Holdings, Inc. competes in the musculoskeletal healthcare sector, including products that can be used in transplant surgeries.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson's medical devices segment offers products that can be used in various surgeries, including organ transplants.
Danaher
DHR
Mkt Cap152.13B
Danaher Corporation's life sciences and diagnostics segments offer products that can be used in the organ transplant process.

About

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Show more...
CEO
Mr. Christoffer Rosenblad
Employees
200
Country
SE
ISIN
SE0004840718
WKN
000A1J5GZ

Listings

0 Comments

Share your thoughts

FAQ

What is Xvivo Perfusion AB stock price today?
The current price of 3XV.F is €22.24 EUR — it has increased by +1.28% in the past 24 hours. Watch Xvivo Perfusion AB stock price performance more closely on the chart.
What is Xvivo Perfusion AB stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xvivo Perfusion AB stocks are traded under the ticker 3XV.F.
Is Xvivo Perfusion AB stock price growing?
3XV.F stock has risen by +8.59% compared to the previous week, the month change is a +38.48% rise, over the last year Xvivo Perfusion AB has showed a -12.61% decrease.
When is the next Xvivo Perfusion AB earnings date?
Xvivo Perfusion AB is going to release the next earnings report on April 24, 2026.
What were Xvivo Perfusion AB earnings last quarter?
3XV.F earnings for the last quarter are 0.09 EUR per share, whereas the estimation was 0.06 EUR resulting in a +52.77% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Xvivo Perfusion AB revenue for the last year?
Xvivo Perfusion AB revenue for the last year amounts to 203.33M EUR.
What is Xvivo Perfusion AB net income for the last year?
3XV.F net income for the last year is 4.04M EUR.
How many employees does Xvivo Perfusion AB have?
As of April 04, 2026, the company has 200 employees.
When did Xvivo Perfusion AB complete a stock split?
Xvivo Perfusion AB has not had any recent stock splits.
Where is Xvivo Perfusion AB headquartered?
Xvivo Perfusion AB is headquartered in Mölndal, SE.